The Market Reports

Index

1 Radiopharmaceuticals in Nuclear Medicine Market Overview
1.1 Product Overview and Scope of Radiopharmaceuticals in Nuclear Medicine
1.2 Radiopharmaceuticals in Nuclear Medicine Segment by Type
1.2.1 Global Radiopharmaceuticals in Nuclear Medicine Sales Growth Rate Comparison by Type (2021-2027)
1.2.2 Diagnostic Radiopharmaceuticals
1.2.3 Therapy Radiopharmaceuticals
1.2.4 Enriched Stable Isotopes
1.3 Radiopharmaceuticals in Nuclear Medicine Segment by Application
1.3.1 Global Radiopharmaceuticals in Nuclear Medicine Sales Comparison by Application: (2021-2027)
1.3.2 Diagnostic Application
1.3.3 Therapeutic Application
1.3.4 Research
1.3.5 Pharmaceutical
1.3.6 Other
1.4 Global Radiopharmaceuticals in Nuclear Medicine Market Size Estimates and Forecasts
1.4.1 Global Radiopharmaceuticals in Nuclear Medicine Revenue 2016-2027
1.4.2 Global Radiopharmaceuticals in Nuclear Medicine Sales 2016-2027
1.4.3 Radiopharmaceuticals in Nuclear Medicine Market Size by Region: 2016 Versus 2021 Versus 2027

2 Radiopharmaceuticals in Nuclear Medicine Market Competition by Manufacturers
2.1 Global Radiopharmaceuticals in Nuclear Medicine Sales Market Share by Manufacturers (2016-2021)
2.2 Global Radiopharmaceuticals in Nuclear Medicine Revenue Market Share by Manufacturers (2016-2021)
2.3 Global Radiopharmaceuticals in Nuclear Medicine Average Price by Manufacturers (2016-2021)
2.4 Manufacturers Radiopharmaceuticals in Nuclear Medicine Manufacturing Sites, Area Served, Product Type
2.5 Radiopharmaceuticals in Nuclear Medicine Market Competitive Situation and Trends
2.5.1 Radiopharmaceuticals in Nuclear Medicine Market Concentration Rate
2.5.2 The Global Top 5 and Top 10 Largest Radiopharmaceuticals in Nuclear Medicine Players Market Share by Revenue
2.5.3 Global Radiopharmaceuticals in Nuclear Medicine Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Radiopharmaceuticals in Nuclear Medicine Retrospective Market Scenario by Region
3.1 Global Radiopharmaceuticals in Nuclear Medicine Retrospective Market Scenario in Sales by Region: 2016-2021
3.2 Global Radiopharmaceuticals in Nuclear Medicine Retrospective Market Scenario in Revenue by Region: 2016-2021
3.3 North America Radiopharmaceuticals in Nuclear Medicine Market Facts & Figures by Country
3.3.1 North America Radiopharmaceuticals in Nuclear Medicine Sales by Country
3.3.2 North America Radiopharmaceuticals in Nuclear Medicine Revenue by Country
3.3.3 U.S.
3.3.4 Canada
3.4 Europe Radiopharmaceuticals in Nuclear Medicine Market Facts & Figures by Country
3.4.1 Europe Radiopharmaceuticals in Nuclear Medicine Sales by Country
3.4.2 Europe Radiopharmaceuticals in Nuclear Medicine Revenue by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific Radiopharmaceuticals in Nuclear Medicine Market Facts & Figures by Region
3.5.1 Asia Pacific Radiopharmaceuticals in Nuclear Medicine Sales by Region
3.5.2 Asia Pacific Radiopharmaceuticals in Nuclear Medicine Revenue by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.5.12 Philippines
3.5.13 Vietnam
3.6 Latin America Radiopharmaceuticals in Nuclear Medicine Market Facts & Figures by Country
3.6.1 Latin America Radiopharmaceuticals in Nuclear Medicine Sales by Country
3.6.2 Latin America Radiopharmaceuticals in Nuclear Medicine Revenue by Country
3.6.3 Mexico
3.6.4 Brazil
3.6.5 Argentina
3.7 Middle East and Africa Radiopharmaceuticals in Nuclear Medicine Market Facts & Figures by Country
3.7.1 Middle East and Africa Radiopharmaceuticals in Nuclear Medicine Sales by Country
3.7.2 Middle East and Africa Radiopharmaceuticals in Nuclear Medicine Revenue by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 U.A.E
4 Global Radiopharmaceuticals in Nuclear Medicine Historic Market Analysis by Type
4.1 Global Radiopharmaceuticals in Nuclear Medicine Sales Market Share by Type (2016-2021)
4.2 Global Radiopharmaceuticals in Nuclear Medicine Revenue Market Share by Type (2016-2021)
4.3 Global Radiopharmaceuticals in Nuclear Medicine Price by Type (2016-2021)

5 Global Radiopharmaceuticals in Nuclear Medicine Historic Market Analysis by Application
5.1 Global Radiopharmaceuticals in Nuclear Medicine Sales Market Share by Application (2016-2021)
5.2 Global Radiopharmaceuticals in Nuclear Medicine Revenue Market Share by Application (2016-2021)
5.3 Global Radiopharmaceuticals in Nuclear Medicine Price by Application (2016-2021)

6 Key Companies Profiled
6.1 Bracco Imaging S.P.A.
6.1.1 Bracco Imaging S.P.A. Corporation Information
6.1.2 Bracco Imaging S.P.A. Description and Business Overview
6.1.3 Bracco Imaging S.P.A. Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2016-2021)
6.1.4 Bracco Imaging S.P.A. Radiopharmaceuticals in Nuclear Medicine Product Portfolio
6.1.5 Bracco Imaging S.P.A. Recent Developments/Updates
6.2 Cambridge Isotope Laboratories, Inc.
6.2.1 Cambridge Isotope Laboratories, Inc. Corporation Information
6.2.2 Cambridge Isotope Laboratories, Inc. Description and Business Overview
6.2.3 Cambridge Isotope Laboratories, Inc. Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2016-2021)
6.2.4 Cambridge Isotope Laboratories, Inc. Radiopharmaceuticals in Nuclear Medicine Product Portfolio
6.2.5 Cambridge Isotope Laboratories, Inc. Recent Developments/Updates
6.3 Cardinal Health, Inc.
6.3.1 Cardinal Health, Inc. Corporation Information
6.3.2 Cardinal Health, Inc. Description and Business Overview
6.3.3 Cardinal Health, Inc. Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2016-2021)
6.3.4 Cardinal Health, Inc. Radiopharmaceuticals in Nuclear Medicine Product Portfolio
6.3.5 Cardinal Health, Inc. Recent Developments/Updates
6.4 Covidien, Plc
6.4.1 Covidien, Plc Corporation Information
6.4.2 Covidien, Plc Description and Business Overview
6.4.3 Covidien, Plc Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2016-2021)
6.4.4 Covidien, Plc Radiopharmaceuticals in Nuclear Medicine Product Portfolio
6.4.5 Covidien, Plc Recent Developments/Updates
6.5 Eczacibasi-Monrol
6.5.1 Eczacibasi-Monrol Corporation Information
6.5.2 Eczacibasi-Monrol Description and Business Overview
6.5.3 Eczacibasi-Monrol Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2016-2021)
6.5.4 Eczacibasi-Monrol Radiopharmaceuticals in Nuclear Medicine Product Portfolio
6.5.5 Eczacibasi-Monrol Recent Developments/Updates
6.6 Fujifilm Holdings Corporation
6.6.1 Fujifilm Holdings Corporation Corporation Information
6.6.2 Fujifilm Holdings Corporation Description and Business Overview
6.6.3 Fujifilm Holdings Corporation Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2016-2021)
6.6.4 Fujifilm Holdings Corporation Radiopharmaceuticals in Nuclear Medicine Product Portfolio
6.6.5 Fujifilm Holdings Corporation Recent Developments/Updates
6.7 GE Healthcare (Subsidiary Of General Electric Company)
6.6.1 GE Healthcare (Subsidiary Of General Electric Company) Corporation Information
6.6.2 GE Healthcare (Subsidiary Of General Electric Company) Description and Business Overview
6.6.3 GE Healthcare (Subsidiary Of General Electric Company) Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2016-2021)
6.4.4 GE Healthcare (Subsidiary Of General Electric Company) Radiopharmaceuticals in Nuclear Medicine Product Portfolio
6.7.5 GE Healthcare (Subsidiary Of General Electric Company) Recent Developments/Updates
6.8 IBA Group
6.8.1 IBA Group Corporation Information
6.8.2 IBA Group Description and Business Overview
6.8.3 IBA Group Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2016-2021)
6.8.4 IBA Group Radiopharmaceuticals in Nuclear Medicine Product Portfolio
6.8.5 IBA Group Recent Developments/Updates
6.9 Isotec, Inc. (Sigma-Aldrich)
6.9.1 Isotec, Inc. (Sigma-Aldrich) Corporation Information
6.9.2 Isotec, Inc. (Sigma-Aldrich) Description and Business Overview
6.9.3 Isotec, Inc. (Sigma-Aldrich) Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2016-2021)
6.9.4 Isotec, Inc. (Sigma-Aldrich) Radiopharmaceuticals in Nuclear Medicine Product Portfolio
6.9.5 Isotec, Inc. (Sigma-Aldrich) Recent Developments/Updates
6.10 Lantheus Medical Imaging, Inc.
6.10.1 Lantheus Medical Imaging, Inc. Corporation Information
6.10.2 Lantheus Medical Imaging, Inc. Description and Business Overview
6.10.3 Lantheus Medical Imaging, Inc. Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2016-2021)
6.10.4 Lantheus Medical Imaging, Inc. Radiopharmaceuticals in Nuclear Medicine Product Portfolio
6.10.5 Lantheus Medical Imaging, Inc. Recent Developments/Updates
6.11 Nordion, Inc.
6.11.1 Nordion, Inc. Corporation Information
6.11.2 Nordion, Inc. Radiopharmaceuticals in Nuclear Medicine Description and Business Overview
6.11.3 Nordion, Inc. Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2016-2021)
6.11.4 Nordion, Inc. Radiopharmaceuticals in Nuclear Medicine Product Portfolio
6.11.5 Nordion, Inc. Recent Developments/Updates
6.12 Ntp Radioisotopes (Pty), Ltd.
6.12.1 Ntp Radioisotopes (Pty), Ltd. Corporation Information
6.12.2 Ntp Radioisotopes (Pty), Ltd. Radiopharmaceuticals in Nuclear Medicine Description and Business Overview
6.12.3 Ntp Radioisotopes (Pty), Ltd. Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2016-2021)
6.12.4 Ntp Radioisotopes (Pty), Ltd. Radiopharmaceuticals in Nuclear Medicine Product Portfolio
6.12.5 Ntp Radioisotopes (Pty), Ltd. Recent Developments/Updates
6.13 Siemens Healthcare (Subsidiary Of Siemens AG)
6.13.1 Siemens Healthcare (Subsidiary Of Siemens AG) Corporation Information
6.13.2 Siemens Healthcare (Subsidiary Of Siemens AG) Radiopharmaceuticals in Nuclear Medicine Description and Business Overview
6.13.3 Siemens Healthcare (Subsidiary Of Siemens AG) Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2016-2021)
6.13.4 Siemens Healthcare (Subsidiary Of Siemens AG) Radiopharmaceuticals in Nuclear Medicine Product Portfolio
6.13.5 Siemens Healthcare (Subsidiary Of Siemens AG) Recent Developments/Updates
6.14 Taiyo Nippon Sanso Corporation
6.14.1 Taiyo Nippon Sanso Corporation Corporation Information
6.14.2 Taiyo Nippon Sanso Corporation Radiopharmaceuticals in Nuclear Medicine Description and Business Overview
6.14.3 Taiyo Nippon Sanso Corporation Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2016-2021)
6.14.4 Taiyo Nippon Sanso Corporation Radiopharmaceuticals in Nuclear Medicine Product Portfolio
6.14.5 Taiyo Nippon Sanso Corporation Recent Developments/Updates
6.15 Urenco Limited
6.15.1 Urenco Limited Corporation Information
6.15.2 Urenco Limited Radiopharmaceuticals in Nuclear Medicine Description and Business Overview
6.15.3 Urenco Limited Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2016-2021)
6.15.4 Urenco Limited Radiopharmaceuticals in Nuclear Medicine Product Portfolio
6.15.5 Urenco Limited Recent Developments/Updates
6.16 Rotem Industries, Ltd., Inc.
6.16.1 Rotem Industries, Ltd., Inc. Corporation Information
6.16.2 Rotem Industries, Ltd., Inc. Radiopharmaceuticals in Nuclear Medicine Description and Business Overview
6.16.3 Rotem Industries, Ltd., Inc. Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2016-2021)
6.16.4 Rotem Industries, Ltd., Inc. Radiopharmaceuticals in Nuclear Medicine Product Portfolio
6.16.5 Rotem Industries, Ltd., Inc. Recent Developments/Updates
6.17 Australian Nuclear Association And Technology Organization (ANSTO)
6.17.1 Australian Nuclear Association And Technology Organization (ANSTO) Corporation Information
6.17.2 Australian Nuclear Association And Technology Organization (ANSTO) Radiopharmaceuticals in Nuclear Medicine Description and Business Overview
6.17.3 Australian Nuclear Association And Technology Organization (ANSTO) Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2016-2021)
6.17.4 Australian Nuclear Association And Technology Organization (ANSTO) Radiopharmaceuticals in Nuclear Medicine Product Portfolio
6.17.5 Australian Nuclear Association And Technology Organization (ANSTO) Recent Developments/Updates
6.18 Board of Radiation And Isotope Technology (BRIT)
6.18.1 Board of Radiation And Isotope Technology (BRIT) Corporation Information
6.18.2 Board of Radiation And Isotope Technology (BRIT) Radiopharmaceuticals in Nuclear Medicine Description and Business Overview
6.18.3 Board of Radiation And Isotope Technology (BRIT) Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2016-2021)
6.18.4 Board of Radiation And Isotope Technology (BRIT) Radiopharmaceuticals in Nuclear Medicine Product Portfolio
6.18.5 Board of Radiation And Isotope Technology (BRIT) Recent Developments/Updates
6.19 Institute of Atomic Energy Polatom Radioisotope Centre
6.19.1 Institute of Atomic Energy Polatom Radioisotope Centre Corporation Information
6.19.2 Institute of Atomic Energy Polatom Radioisotope Centre Radiopharmaceuticals in Nuclear Medicine Description and Business Overview
6.19.3 Institute of Atomic Energy Polatom Radioisotope Centre Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2016-2021)
6.19.4 Institute of Atomic Energy Polatom Radioisotope Centre Radiopharmaceuticals in Nuclear Medicine Product Portfolio
6.19.5 Institute of Atomic Energy Polatom Radioisotope Centre Recent Developments/Updates
6.20 Institute of Isotopes Co., Ltd.
6.20.1 Institute of Isotopes Co., Ltd. Corporation Information
6.20.2 Institute of Isotopes Co., Ltd. Radiopharmaceuticals in Nuclear Medicine Description and Business Overview
6.20.3 Institute of Isotopes Co., Ltd. Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2016-2021)
6.20.4 Institute of Isotopes Co., Ltd. Radiopharmaceuticals in Nuclear Medicine Product Portfolio
6.20.5 Institute of Isotopes Co., Ltd. Recent Developments/Updates
6.21 Institute Of Radioelement (IRE)
6.21.1 Institute Of Radioelement (IRE) Corporation Information
6.21.2 Institute Of Radioelement (IRE) Radiopharmaceuticals in Nuclear Medicine Description and Business Overview
6.21.3 Institute Of Radioelement (IRE) Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2016-2021)
6.21.4 Institute Of Radioelement (IRE) Radiopharmaceuticals in Nuclear Medicine Product Portfolio
6.21.5 Institute Of Radioelement (IRE) Recent Developments/Updates

7 Radiopharmaceuticals in Nuclear Medicine Manufacturing Cost Analysis
7.1 Radiopharmaceuticals in Nuclear Medicine Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of Radiopharmaceuticals in Nuclear Medicine
7.4 Radiopharmaceuticals in Nuclear Medicine Industrial Chain Analysis

8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 Radiopharmaceuticals in Nuclear Medicine Distributors List
8.3 Radiopharmaceuticals in Nuclear Medicine Customers

9 Radiopharmaceuticals in Nuclear Medicine Market Dynamics
9.1 Radiopharmaceuticals in Nuclear Medicine Industry Trends
9.2 Radiopharmaceuticals in Nuclear Medicine Growth Drivers
9.3 Radiopharmaceuticals in Nuclear Medicine Market Challenges
9.4 Radiopharmaceuticals in Nuclear Medicine Market Restraints

10 Global Market Forecast
10.1 Radiopharmaceuticals in Nuclear Medicine Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of Radiopharmaceuticals in Nuclear Medicine by Type (2022-2027)
10.1.2 Global Forecasted Revenue of Radiopharmaceuticals in Nuclear Medicine by Type (2022-2027)
10.2 Radiopharmaceuticals in Nuclear Medicine Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of Radiopharmaceuticals in Nuclear Medicine by Application (2022-2027)
10.2.2 Global Forecasted Revenue of Radiopharmaceuticals in Nuclear Medicine by Application (2022-2027)
10.3 Radiopharmaceuticals in Nuclear Medicine Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of Radiopharmaceuticals in Nuclear Medicine by Region (2022-2027)
10.3.2 Global Forecasted Revenue of Radiopharmaceuticals in Nuclear Medicine by Region (2022-2027)

11 Research Finding and Conclusion

12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer

List of Tables

List of Tables
Table 1. Global Radiopharmaceuticals in Nuclear Medicine Sales (K MT) Growth Rate Comparison by Type (2021-2027)
Table 2. Global Radiopharmaceuticals in Nuclear Medicine Sales (K MT) Comparison by Application (2021-2027)
Table 3. Global Radiopharmaceuticals in Nuclear Medicine Market Size by Region (US$ Million) (2016 VS 2021 VS 2027)
Table 4. Key Manufacturers Radiopharmaceuticals in Nuclear Medicine Covered in This Study
Table 5. Global Radiopharmaceuticals in Nuclear Medicine Sales (K MT) of Key Manufacturers (2016-2021)
Table 6. Global Radiopharmaceuticals in Nuclear Medicine Sales Market Share by Manufacturers (2016-2021)
Table 7. Global Radiopharmaceuticals in Nuclear Medicine Revenue (US$ Million) by Manufacturers (2016-2021)
Table 8. Global Radiopharmaceuticals in Nuclear Medicine Revenue Share by Manufacturers (2016-2021)
Table 9. Global Market Radiopharmaceuticals in Nuclear Medicine Average Price (USD/MT) of Key Manufacturers (2016-2021)
Table 10. Manufacturers Radiopharmaceuticals in Nuclear Medicine Manufacturing Sites and Area Served
Table 11. Manufacturers Radiopharmaceuticals in Nuclear Medicine Product Type
Table 12. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 13. Global Radiopharmaceuticals in Nuclear Medicine by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Radiopharmaceuticals in Nuclear Medicine as of 2020)
Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 15. Global Radiopharmaceuticals in Nuclear Medicine Sales by Region (2016-2021) & (K MT)
Table 16. Global Radiopharmaceuticals in Nuclear Medicine Sales Market Share by Region (2016-2021)
Table 17. Global Radiopharmaceuticals in Nuclear Medicine Revenue by Region (2016-2021) & (US$ Million)
Table 18. North America Radiopharmaceuticals in Nuclear Medicine Sales by Country (2016-2021) & (K MT)
Table 19. North America Radiopharmaceuticals in Nuclear Medicine Sales Market Share by Country (2016-2021)
Table 20. North America Radiopharmaceuticals in Nuclear Medicine Revenue by Country (2016-2021) & (US$ Million)
Table 21. North America Radiopharmaceuticals in Nuclear Medicine Revenue Market Share by Country (2016-2021)
Table 22. Europe Radiopharmaceuticals in Nuclear Medicine Sales by Country (2016-2021) & (K MT)
Table 23. Europe Radiopharmaceuticals in Nuclear Medicine Sales Market Share by Country (2016-2021)
Table 24. Europe Radiopharmaceuticals in Nuclear Medicine Revenue by Country (2016-2021) & (US$ Million)
Table 25. Europe Radiopharmaceuticals in Nuclear Medicine Revenue Market Share by Country (2016-2021)
Table 26. Asia Pacific Radiopharmaceuticals in Nuclear Medicine Sales by Region (2016-2021) & (K MT)
Table 27. Asia Pacific Radiopharmaceuticals in Nuclear Medicine Sales Market Share by Region (2016-2021)
Table 28. Asia Pacific Radiopharmaceuticals in Nuclear Medicine Revenue by Region (2016-2021) & (US$ Million)
Table 29. Asia Pacific Radiopharmaceuticals in Nuclear Medicine Revenue Market Share by Region (2016-2021)
Table 30. Latin America Radiopharmaceuticals in Nuclear Medicine Sales by Country (2016-2021) & (K MT)
Table 31. Latin America Radiopharmaceuticals in Nuclear Medicine Sales Market Share by Country (2016-2021)
Table 32. Latin America Radiopharmaceuticals in Nuclear Medicine Revenue by Country (2016-2021) & (US$ Million)
Table 33. Latin America Radiopharmaceuticals in Nuclear Medicine Revenue Market Share by Country (2016-2021)
Table 34. Middle East and Africa Radiopharmaceuticals in Nuclear Medicine Sales by Country (2016-2021) & (K MT)
Table 35. Middle East and Africa Radiopharmaceuticals in Nuclear Medicine Sales Market Share by Country (2016-2021)
Table 36. Middle East and Africa Radiopharmaceuticals in Nuclear Medicine Revenue by Country (2016-2021) & (US$ Million)
Table 37. Middle East and Africa Radiopharmaceuticals in Nuclear Medicine Revenue Market Share by Country (2016-2021)
Table 38. Global Radiopharmaceuticals in Nuclear Medicine Sales (K MT) by Type (2016-2021)
Table 39. Global Radiopharmaceuticals in Nuclear Medicine Sales Market Share by Type (2016-2021)
Table 40. Global Radiopharmaceuticals in Nuclear Medicine Revenue (Million US$) by Type (2016-2021)
Table 41. Global Radiopharmaceuticals in Nuclear Medicine Revenue Share by Type (2016-2021)
Table 42. Global Radiopharmaceuticals in Nuclear Medicine Price (USD/MT) by Type (2016-2021)
Table 43. Global Radiopharmaceuticals in Nuclear Medicine Sales (K MT) by Application (2016-2021)
Table 44. Global Radiopharmaceuticals in Nuclear Medicine Sales Market Share by Application (2016-2021)
Table 45. Global Radiopharmaceuticals in Nuclear Medicine Revenue (Million US$) by Application (2016-2021)
Table 46. Global Radiopharmaceuticals in Nuclear Medicine Revenue Share by Application (2016-2021)
Table 47. Global Radiopharmaceuticals in Nuclear Medicine Price (USD/MT) by Application (2016-2021)
Table 48. Bracco Imaging S.P.A. Corporation Information
Table 49. Bracco Imaging S.P.A. Description and Business Overview
Table 50. Bracco Imaging S.P.A. Radiopharmaceuticals in Nuclear Medicine Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2016-2021)
Table 51. Bracco Imaging S.P.A. Radiopharmaceuticals in Nuclear Medicine Product
Table 52. Bracco Imaging S.P.A. Recent Developments/Updates
Table 53. Cambridge Isotope Laboratories, Inc. Corporation Information
Table 54. Cambridge Isotope Laboratories, Inc. Description and Business Overview
Table 55. Cambridge Isotope Laboratories, Inc. Radiopharmaceuticals in Nuclear Medicine Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2016-2021)
Table 56. Cambridge Isotope Laboratories, Inc. Radiopharmaceuticals in Nuclear Medicine Product
Table 57. Cambridge Isotope Laboratories, Inc. Recent Developments/Updates
Table 58. Cardinal Health, Inc. Corporation Information
Table 59. Cardinal Health, Inc. Description and Business Overview
Table 60. Cardinal Health, Inc. Radiopharmaceuticals in Nuclear Medicine Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2016-2021)
Table 61. Cardinal Health, Inc. Radiopharmaceuticals in Nuclear Medicine Product
Table 62. Cardinal Health, Inc. Recent Developments/Updates
Table 63. Covidien, Plc Corporation Information
Table 64. Covidien, Plc Description and Business Overview
Table 65. Covidien, Plc Radiopharmaceuticals in Nuclear Medicine Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2016-2021)
Table 66. Covidien, Plc Radiopharmaceuticals in Nuclear Medicine Product
Table 67. Covidien, Plc Recent Developments/Updates
Table 68. Eczacibasi-Monrol Corporation Information
Table 69. Eczacibasi-Monrol Description and Business Overview
Table 70. Eczacibasi-Monrol Radiopharmaceuticals in Nuclear Medicine Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2016-2021)
Table 71. Eczacibasi-Monrol Radiopharmaceuticals in Nuclear Medicine Product
Table 72. Eczacibasi-Monrol Recent Developments/Updates
Table 73. Fujifilm Holdings Corporation Corporation Information
Table 74. Fujifilm Holdings Corporation Description and Business Overview
Table 75. Fujifilm Holdings Corporation Radiopharmaceuticals in Nuclear Medicine Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2016-2021)
Table 76. Fujifilm Holdings Corporation Radiopharmaceuticals in Nuclear Medicine Product
Table 77. Fujifilm Holdings Corporation Recent Developments/Updates
Table 78. GE Healthcare (Subsidiary Of General Electric Company) Corporation Information
Table 79. GE Healthcare (Subsidiary Of General Electric Company) Description and Business Overview
Table 80. GE Healthcare (Subsidiary Of General Electric Company) Radiopharmaceuticals in Nuclear Medicine Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2016-2021)
Table 81. GE Healthcare (Subsidiary Of General Electric Company) Radiopharmaceuticals in Nuclear Medicine Product
Table 82. GE Healthcare (Subsidiary Of General Electric Company) Recent Developments/Updates
Table 83. IBA Group Corporation Information
Table 84. IBA Group Description and Business Overview
Table 85. IBA Group Radiopharmaceuticals in Nuclear Medicine Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2016-2021)
Table 86. IBA Group Radiopharmaceuticals in Nuclear Medicine Product
Table 87. IBA Group Recent Developments/Updates
Table 88. Isotec, Inc. (Sigma-Aldrich) Corporation Information
Table 89. Isotec, Inc. (Sigma-Aldrich) Description and Business Overview
Table 90. Isotec, Inc. (Sigma-Aldrich) Radiopharmaceuticals in Nuclear Medicine Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2016-2021)
Table 91. Isotec, Inc. (Sigma-Aldrich) Radiopharmaceuticals in Nuclear Medicine Product
Table 92. Isotec, Inc. (Sigma-Aldrich) Recent Developments/Updates
Table 93. Lantheus Medical Imaging, Inc. Corporation Information
Table 94. Lantheus Medical Imaging, Inc. Description and Business Overview
Table 95. Lantheus Medical Imaging, Inc. Radiopharmaceuticals in Nuclear Medicine Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2016-2021)
Table 96. Lantheus Medical Imaging, Inc. Radiopharmaceuticals in Nuclear Medicine Product
Table 97. Lantheus Medical Imaging, Inc. Recent Developments/Updates
Table 98. Nordion, Inc. Corporation Information
Table 99. Nordion, Inc. Description and Business Overview
Table 100. Nordion, Inc. Radiopharmaceuticals in Nuclear Medicine Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2016-2021)
Table 101. Nordion, Inc. Radiopharmaceuticals in Nuclear Medicine Product
Table 102. Nordion, Inc. Recent Developments/Updates
Table 103. Ntp Radioisotopes (Pty), Ltd. Corporation Information
Table 104. Ntp Radioisotopes (Pty), Ltd. Description and Business Overview
Table 105. Ntp Radioisotopes (Pty), Ltd. Radiopharmaceuticals in Nuclear Medicine Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2016-2021)
Table 106. Ntp Radioisotopes (Pty), Ltd. Radiopharmaceuticals in Nuclear Medicine Product
Table 107. Ntp Radioisotopes (Pty), Ltd. Recent Developments/Updates
Table 108. Siemens Healthcare (Subsidiary Of Siemens AG) Corporation Information
Table 109. Siemens Healthcare (Subsidiary Of Siemens AG) Description and Business Overview
Table 110. Siemens Healthcare (Subsidiary Of Siemens AG) Radiopharmaceuticals in Nuclear Medicine Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2016-2021)
Table 111. Siemens Healthcare (Subsidiary Of Siemens AG) Radiopharmaceuticals in Nuclear Medicine Product
Table 112. Siemens Healthcare (Subsidiary Of Siemens AG) Recent Developments/Updates
Table 113. Taiyo Nippon Sanso Corporation Corporation Information
Table 114. Taiyo Nippon Sanso Corporation Description and Business Overview
Table 115. Taiyo Nippon Sanso Corporation Radiopharmaceuticals in Nuclear Medicine Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2016-2021)
Table 116. Taiyo Nippon Sanso Corporation Radiopharmaceuticals in Nuclear Medicine Product
Table 117. Taiyo Nippon Sanso Corporation Recent Developments/Updates
Table 118. Urenco Limited Corporation Information
Table 119. Urenco Limited Description and Business Overview
Table 120. Urenco Limited Radiopharmaceuticals in Nuclear Medicine Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2016-2021)
Table 121. Urenco Limited Radiopharmaceuticals in Nuclear Medicine Product
Table 122. Urenco Limited Recent Developments/Updates
Table 123. Rotem Industries, Ltd., Inc. Corporation Information
Table 124. Rotem Industries, Ltd., Inc. Description and Business Overview
Table 125. Rotem Industries, Ltd., Inc. Radiopharmaceuticals in Nuclear Medicine Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2016-2021)
Table 126. Rotem Industries, Ltd., Inc. Radiopharmaceuticals in Nuclear Medicine Product
Table 127. Rotem Industries, Ltd., Inc. Recent Developments/Updates
Table 128. Australian Nuclear Association And Technology Organization (ANSTO) Corporation Information
Table 129. Australian Nuclear Association And Technology Organization (ANSTO) Description and Business Overview
Table 130. Australian Nuclear Association And Technology Organization (ANSTO) Radiopharmaceuticals in Nuclear Medicine Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2016-2021)
Table 131. Australian Nuclear Association And Technology Organization (ANSTO) Radiopharmaceuticals in Nuclear Medicine Product
Table 132. Australian Nuclear Association And Technology Organization (ANSTO) Recent Developments/Updates
Table 133. Board of Radiation And Isotope Technology (BRIT) Corporation Information
Table 134. Board of Radiation And Isotope Technology (BRIT) Description and Business Overview
Table 135. Board of Radiation And Isotope Technology (BRIT) Radiopharmaceuticals in Nuclear Medicine Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2016-2021)
Table 136. Board of Radiation And Isotope Technology (BRIT) Radiopharmaceuticals in Nuclear Medicine Product
Table 137. Board of Radiation And Isotope Technology (BRIT) Recent Developments/Updates
Table 138. Institute of Atomic Energy Polatom Radioisotope Centre Corporation Information
Table 139. Institute of Atomic Energy Polatom Radioisotope Centre Description and Business Overview
Table 140. Institute of Atomic Energy Polatom Radioisotope Centre Radiopharmaceuticals in Nuclear Medicine Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2016-2021)
Table 141. Institute of Atomic Energy Polatom Radioisotope Centre Radiopharmaceuticals in Nuclear Medicine Product
Table 142. Institute of Atomic Energy Polatom Radioisotope Centre Recent Developments/Updates
Table 143. Institute of Isotopes Co., Ltd. Corporation Information
Table 144. Institute of Isotopes Co., Ltd. Description and Business Overview
Table 145. Institute of Isotopes Co., Ltd. Radiopharmaceuticals in Nuclear Medicine Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2016-2021)
Table 146. Institute of Isotopes Co., Ltd. Radiopharmaceuticals in Nuclear Medicine Product
Table 147. Institute of Isotopes Co., Ltd. Recent Developments/Updates
Table 148. Institute Of Radioelement (IRE) Corporation Information
Table 149. Institute Of Radioelement (IRE) Description and Business Overview
Table 150. Institute Of Radioelement (IRE) Radiopharmaceuticals in Nuclear Medicine Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2016-2021)
Table 151. Institute Of Radioelement (IRE) Radiopharmaceuticals in Nuclear Medicine Product
Table 152. Institute Of Radioelement (IRE) Recent Developments/Updates
Table 153. Production Base and Market Concentration Rate of Raw Material
Table 154. Key Suppliers of Raw Materials
Table 155. Radiopharmaceuticals in Nuclear Medicine Distributors List
Table 156. Radiopharmaceuticals in Nuclear Medicine Customers List
Table 157. Radiopharmaceuticals in Nuclear Medicine Market Trends
Table 158. Radiopharmaceuticals in Nuclear Medicine Growth Drivers
Table 159. Radiopharmaceuticals in Nuclear Medicine Market Challenges
Table 160. Radiopharmaceuticals in Nuclear Medicine Market Restraints
Table 161. Global Radiopharmaceuticals in Nuclear Medicine Sales Forecast by Type (2022-2027) & (K MT)
Table 162. Global Radiopharmaceuticals in Nuclear Medicine Sales Market Share Forecast by Type (2022-2027)
Table 163. Global Radiopharmaceuticals in Nuclear Medicine Revenue Forecast by Type (2022-2027) & (US$ Million)
Table 164. Global Radiopharmaceuticals in Nuclear Medicine Revenue Market Share Forecast by Type (2022-2027)
Table 165. Global Radiopharmaceuticals in Nuclear Medicine Sales Forecast by Application (2022-2027) & (K MT)
Table 166. Global Radiopharmaceuticals in Nuclear Medicine Sales Market Share Forecast by Application (2022-2027)
Table 167. Global Radiopharmaceuticals in Nuclear Medicine Revenue Forecast by Application (2022-2027) & (US$ Million)
Table 168. Global Radiopharmaceuticals in Nuclear Medicine Revenue Market Share Forecast by Application (2022-2027)
Table 169. Global Radiopharmaceuticals in Nuclear Medicine Sales Forecast by Region (2022-2027) & (K MT)
Table 170. Global Radiopharmaceuticals in Nuclear Medicine Sales Market Share Forecast by Region (2022-2027)
Table 171. Global Radiopharmaceuticals in Nuclear Medicine Revenue Forecast by Region (2022-2027) & (US$ Million)
Table 172. Global Radiopharmaceuticals in Nuclear Medicine Revenue Market Share Forecast by Region (2022-2027)
Table 173. Research Programs/Design for This Report
Table 174. Key Data Information from Secondary Sources
Table 175. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Radiopharmaceuticals in Nuclear Medicine
Figure 2. Global Radiopharmaceuticals in Nuclear Medicine Market Share by Type in 2020 & 2027
Figure 3. Diagnostic Radiopharmaceuticals Product Picture
Figure 4. Therapy Radiopharmaceuticals Product Picture
Figure 5. Enriched Stable Isotopes Product Picture
Figure 6. Global Radiopharmaceuticals in Nuclear Medicine Market Share by Application in 2020 & 2027
Figure 7. Diagnostic Application
Figure 8. Therapeutic Application
Figure 9. Research
Figure 10. Pharmaceutical
Figure 11. Other
Figure 12. Global Radiopharmaceuticals in Nuclear Medicine Revenue, (US$ Million), 2016 VS 2021 VS 2027
Figure 13. Global Radiopharmaceuticals in Nuclear Medicine Market Size 2016-2027 (US$ Million)
Figure 14. Global Radiopharmaceuticals in Nuclear Medicine Sales 2016-2027 (K MT)
Figure 15. Global Radiopharmaceuticals in Nuclear Medicine Market Size Market Share by Region: 2016 VS 20210 VS 2027
Figure 16. Radiopharmaceuticals in Nuclear Medicine Sales Share by Manufacturers in 2020
Figure 17. Global Radiopharmaceuticals in Nuclear Medicine Revenue Share by Manufacturers in 2020
Figure 18. The Global 5 and 10 Largest Radiopharmaceuticals in Nuclear Medicine Players: Market Share by Revenue in 2020
Figure 19. Radiopharmaceuticals in Nuclear Medicine Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2016 VS 2021
Figure 20. Global Radiopharmaceuticals in Nuclear Medicine Sales Market Share by Region (2016-2021)
Figure 21. Global Radiopharmaceuticals in Nuclear Medicine Sales Market Share by Region in 2020
Figure 22. Global Radiopharmaceuticals in Nuclear Medicine Revenue Market Share by Region (2016-2021)
Figure 23. Global Radiopharmaceuticals in Nuclear Medicine Revenue Market Share by Region in 2020
Figure 24. U.S. Radiopharmaceuticals in Nuclear Medicine Revenue Growth Rate (2016-2021) (US$ Million)
Figure 25. Canada Radiopharmaceuticals in Nuclear Medicine Revenue Growth Rate (2016-2021) (US$ Million)
Figure 26. Germany Radiopharmaceuticals in Nuclear Medicine Revenue Growth Rate (2016-2021) (US$ Million)
Figure 27. France Radiopharmaceuticals in Nuclear Medicine Revenue Growth Rate (2016-2021) (US$ Million)
Figure 28. U.K. Radiopharmaceuticals in Nuclear Medicine Revenue Growth Rate (2016-2021) (US$ Million)
Figure 29. Italy Radiopharmaceuticals in Nuclear Medicine Revenue Growth Rate (2016-2021) (US$ Million)
Figure 30. Russia Radiopharmaceuticals in Nuclear Medicine Revenue Growth Rate (2016-2021) (US$ Million)
Figure 31. China Radiopharmaceuticals in Nuclear Medicine Revenue Growth Rate (2016-2021) (US$ Million)
Figure 32. Japan Radiopharmaceuticals in Nuclear Medicine Revenue Growth Rate (2016-2021) (US$ Million)
Figure 33. South Korea Radiopharmaceuticals in Nuclear Medicine Revenue Growth Rate (2016-2021) (US$ Million)
Figure 34. India Radiopharmaceuticals in Nuclear Medicine Revenue Growth Rate (2016-2021) (US$ Million)
Figure 35. Australia Radiopharmaceuticals in Nuclear Medicine Revenue Growth Rate (2016-2021) (US$ Million)
Figure 36. Taiwan Radiopharmaceuticals in Nuclear Medicine Revenue Growth Rate (2016-2021) (US$ Million)
Figure 37. Indonesia Radiopharmaceuticals in Nuclear Medicine Revenue Growth Rate (2016-2021) (US$ Million)
Figure 38. Thailand Radiopharmaceuticals in Nuclear Medicine Revenue Growth Rate (2016-2021) (US$ Million)
Figure 39. Malaysia Radiopharmaceuticals in Nuclear Medicine Revenue Growth Rate (2016-2021) (US$ Million)
Figure 40. Philippines Radiopharmaceuticals in Nuclear Medicine Revenue Growth Rate (2016-2021) (US$ Million)
Figure 41. Vietnam Radiopharmaceuticals in Nuclear Medicine Revenue Growth Rate (2016-2021) (US$ Million)
Figure 42. Mexico Radiopharmaceuticals in Nuclear Medicine Revenue Growth Rate (2016-2021) (US$ Million)
Figure 43. Brazil Radiopharmaceuticals in Nuclear Medicine Revenue Growth Rate (2016-2021) (US$ Million)
Figure 44. Argentina Radiopharmaceuticals in Nuclear Medicine Revenue Growth Rate (2016-2021) (US$ Million)
Figure 45. Turkey Radiopharmaceuticals in Nuclear Medicine Revenue Growth Rate (2016-2021) (US$ Million)
Figure 46. Saudi Arabia Radiopharmaceuticals in Nuclear Medicine Revenue Growth Rate (2016-2021) (US$ Million)
Figure 47. U.A.E Radiopharmaceuticals in Nuclear Medicine Revenue Growth Rate (2016-2021) (US$ Million)
Figure 48. Sales Market Share of Radiopharmaceuticals in Nuclear Medicine by Type (2016-2021)
Figure 49. Sales Market Share of Radiopharmaceuticals in Nuclear Medicine by Application (2016-2021)
Figure 50. Sales Market Share of Radiopharmaceuticals in Nuclear Medicine by Application in 2020
Figure 51. Revenue Share of Radiopharmaceuticals in Nuclear Medicine by Application (2016-2021)
Figure 52. Revenue Share of Radiopharmaceuticals in Nuclear Medicine by Application in 2020
Figure 53. Manufacturing Cost Structure of Radiopharmaceuticals in Nuclear Medicine
Figure 54. Manufacturing Process Analysis of Radiopharmaceuticals in Nuclear Medicine
Figure 55. Radiopharmaceuticals in Nuclear Medicine Industrial Chain Analysis
Figure 56. Channels of Distribution
Figure 57. Distributors Profiles
Figure 58. Bottom-up and Top-down Approaches for This Report
Figure 59. Data Triangulation
Figure 60. Key Executives Interviewed